Adjuvant chemoradiotherapy plus PD-1 inhibitor for pN3 gastric cancer: a randomized, multicenter, Phase III trial.
Wang Yang, Menglong Zhou, Guichao Li, Changming Zhou, Lei Wang, Fan Xia, Hui Zhang, Lijun Shen, Yan Wang, Juefeng Wan, Yaqi Wang, Guangfa Zhao, Zhen Zhang
Future Oncol 20(40) 3389-3396
摘要
摘要
D2 surgery followed by adjuvant chemotherapy has been established as the standard of care for patients with locally advanced gastric cancer in Asian countries. However, its efficacy is still unsatisfactory, especially for pathological N3 disease. The RACING trial is a randomized, multicenter, Phase III trial designed to compare the efficacy and safety of chemotherapy alone versus chemotherapy in combination with PD-1 inhibitor and radiotherapy in patients with pN3 gastric or gastroesophageal junction adenocarcinoma. A total of 433 patients will be assigned at a 1:1 ratio to the two arms. The primary end point is the 3-year disease-free survival rate. The secondary end points include the 3-year overall survival rate, 3-year local recurrence-free survival rate, treatment-related adverse events and quality of life.Clinical Trial Registration: NCT04997837 (ClinicalTrials.gov).
KM 提取结果
0 个 Figure · 0 个 KM 面板